Chronic granulocytic leukemia is defined as chronic granulocytic leukemia, and the first three months of treatment are more critical. Tyrosine kinase inhibitors (e.g., imatinib) are preferred for the treatment of chronic granulocytic leukemia, and an important indicator of the effectiveness of the treatment in the early stage is the level of the BCR-ABL fusion gene at 3 months of tyrosine kinase inhibitor treatment. If this fusion gene turns negative, it indicates a better efficacy of treatment, and thereafter long-term tyrosine kinase inhibitor administration is required. If there is no turnaround, adjustments need to be made based on the decreasing log level. The more complete the remission of chronic granulocytic leukemia during the first 3 months of medication, the better the long-term prognosis when efficacy is evaluated. If the medication is not taken regularly, even if the blood picture achieves complete remission, its cytogenetics and molecular biology will still affect long-term survival when remission is not achieved. When suffering from chronic granulocytic leukemia, one should standardize the treatment under the guidance of a doctor and adhere to the medication.